6.64% volatility in CRISPR Therapeutics AG (CRSP) last month: This is a red flag warning

On Friday, CRISPR Therapeutics AG (NASDAQ: CRSP) opened higher 14.71% from the last session, before settling in for the closing price of $34.26. Price fluctuations for CRSP have ranged from $30.04 to $67.88 over the past 52 weeks.

A company in the Healthcare sector has jumped its sales by 31550.17% annually for the last half of the decade. Company’s average yearly earnings per share was noted -9.43% at the time writing. With a float of $82.46 million, this company’s outstanding shares have now reached $85.74 million.

In an organization with 393 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -227.47%, operating margin of -1273.97%, and the pretax margin is -990.27%.

CRISPR Therapeutics AG (CRSP) Insider Updates

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of CRISPR Therapeutics AG is 4.33%, while institutional ownership is 69.04%. The most recent insider transaction that took place on Mar 21 ’25, was worth 413,578. In this transaction Chief Executive Officer of this company sold 10,031 shares at a rate of $41.23, taking the stock ownership to the 195,085 shares. Before that another transaction happened on Mar 21 ’25, when Company’s Chief Operating Officer sold 1,714 for $41.23, making the entire transaction worth $70,668. This insider now owns 10,544 shares in total.

CRISPR Therapeutics AG (CRSP) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.26 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -9.43% per share during the next fiscal year.

CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators

Check out the current performance indicators for CRISPR Therapeutics AG (CRSP). In the past quarter, the stock posted a quick ratio of 22.07. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 90.79.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.36, a number that is poised to hit -1.21 in the next quarter and is forecasted to reach -3.94 in one year’s time.

Technical Analysis of CRISPR Therapeutics AG (CRSP)

Let’s dig in a bit further. During the last 5-days, its volume was 3.59 million. That was better than the volume of 2.25 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 77.78%. Additionally, its Average True Range was 2.80.

During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 35.84%, which indicates a significant decrease from 74.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 92.79% in the past 14 days, which was higher than the 62.93% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $41.26, while its 200-day Moving Average is $46.42. However, in the short run, CRISPR Therapeutics AG’s stock first resistance to watch stands at $40.92. Second resistance stands at $42.54. The third major resistance level sits at $45.78. If the price goes on to break the first support level at $36.06, it is likely to go to the next support level at $32.82. Assuming the price breaks the second support level, the third support level stands at $31.20.

CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats

There are currently 85,774K shares outstanding in the company with a market cap of 3.39 billion. Presently, the company’s annual sales total 37,310 K according to its annual income of -366,250 K. Last quarter, the company’s sales amounted to 35,690 K and its income totaled -37,310 K.